U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H32O2
Molecular Weight 316.4776
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BOLASTERONE

SMILES

[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])[C@H](C)CC4=CC(=O)CC[C@]34C

InChI

InChIKey=IVFYLRMMHVYGJH-VLOLGRDOSA-N
InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16+,17+,18-,19+,20+,21+/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H32O2
Molecular Weight 316.4776
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Bolasterone (7α, 17α‐dimethyltestosterone) is an anabolic steroid. It is able to activate androgen receptor. Despite being a testosterone derivative, bolasterone is also much more anabolic than androgenic in nature. At a given therapeutic level, it is much less likely to cause androgenic/virilizing side effects. he drug was developed by Upjohn, and sold in the U.S. during the 1960’s under the Myagen brand name. It was mainly indicated for the treatment of advanced breast cancer in women, although the agent was also investigated for its stimulatory effect on blood cells and its general anabolic (lean-tissue sparing) activity. Bolasterone was ultimately a short-lived drug, disappearing from the U.S. market shortly after its release.

Originator

Approval Year

PubMed

Substance Class Chemical
Record UNII
T7ZM08F7FU
Record Status Validated (UNII)
Record Version